Previous human studies have shown that the analgesic effect of high-frequency TENS could not be reversed by low doses of naloxone. The aim of the present study was to reinvestigate the possible contribution of opioid receptors to high-frequency TENS analgesia by using low (0.02 mg/kg) and high (0.14 mg/kg) doses of naloxone. Naloxone (high and low doses) and saline were administered intravenously to young healthy adults using a triple-blind randomized cross-over design. For each visit, TENS (100 Hz, 60 ls) was applied for 25 min to the external surface of the left ankle. TENS intensity was adjusted to obtain strong but comfortable (innocuous) paresthesias. Experimental pain was evoked with a 1 cm 2 thermode applied on the lateral aspect of the left heel. Subjective pain scores were obtained before, during and after TENS. Because preliminary analyses showed that the order of presentation affected the pattern of results, only the first visit of every participant could be analyzed without fear of contamination from possible carry-over effects. These revealed that TENS maintained its analgesic properties following the injection of saline (p < .001) and the injection of a low dose of naloxone (p < .05). However, when a high dose of naloxone was administered, TENS analgesia was completely blocked (p = .20). These results suggest that high-frequency TENS involves opioid receptors. An insufficient amount of opioid antagonist likely prevented previous human studies from discovering the importance of opioid receptors in producing high-frequency TENS analgesia. Ó
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Introduction
Transcutaneous electrical nerve stimulation (TENS) is a noninvasive modality commonly used in rehabilitation for pain relief [20] . Scientific rationale behind low-intensity/high-frequency TENS (also known as conventional-mode TENS) is generally based on the gate-theory proposed by Melzack and Wall [19] where stimulation of non-nociceptive afferents (Ab fibers) inhibits the nociceptive signal transmitted by Ad and C fibers. The release of endogenous opioids following high-frequency TENS application has also been proposed as a possible mechanism of action [9, 22] . This latter premise was, however, refuted by the work of several authors who showed that the analgesic properties of high-frequency TENS could not be reversed by the opioid antagonist naloxone These results led to the conclusion that the analgesia induced by high-frequency TENS is mediated by d receptors and that the failure of naloxone to reverse high-frequency TENS analgesia in previous studies was due to the inability of the antagonist to block d receptors with the low doses used.
Based on these results from animal studies, the purpose of this study was to reinvestigate the implication of opioid receptors in the analgesia induced by high-frequency TENS in human subjects by using high (0.14 mg/kg) and low (0.02 mg/kg) doses of naloxone. Considering the work of Sluka and colleagues [15, 25] and based on previous naloxone studies in humans [1,10,13,14,17, 24,29], we hypothesized that the high -but not the low -dose of naloxone would reverse the analgesia induced by high-frequency TENS.
